Effect of Medications on Physical Function and Cognition in Nursing Home Residents with Dementia
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objectives: To assess the effectiveness of medications used in the management of Alzheimer's disease and related dementias ( ADRD ) on cognition and activity of daily living ( ADL ) trajectories and to determine whether sex modifies these effects. Design: Two‐year (2007–2008) longitudinal study. Setting: Medicare enrollment and claims data linked to the Minimum Dataset 2.0. Participants: Older nursing home ( NH ) residents with newly diagnosed ADRD (n = 18,950). Measurements: Exposures included four medication classes: antidementia medications ( ADM s), antipsychotics, antidepressants, and mood stabilizers. Outcomes included ADL s and cognition (Cognitive Performance Scale ( CPS )). Marginal structural models were employed to account for time‐dependent confounding. Results: The mean age was 83.6, and 76% of the sample was female. Baseline use of ADM s was 15%, antidepressants was 40%, antipsychotics was 13%, and mood stabilizers was 3%. Mean baseline ADL and CPS scores were 16.6 and 2.1, respectively. ADM use was not associated with change in ADL s over time but was associated with a slower CPS decline (slope difference: −0.09 points/year, 99% confidence interval ( CI ) = −0.14 to −0.03). Antidepressant use was associated with slower declines in ADL (slope difference: −0.36 points/year, 99% CI = −0.58 to −0.14) and CPS (slope difference: −0.12 points/year, 99% CI = −0.17 to −0.08). Sex modified the effect of both antipsychotic and mood stabilizer use on ADL s; female users declined most quickly. Antipsychotic use was associated with slower CPS decline (slope difference: −0.11 points/year, 99% CI = −0.17 to −0.06), whereas mood stabilizer use had no effect. Conclusion: Despite the observed statistically significantly slower declines in cognition with ADM s, antidepressants, and antipsychotics and the slower ADL decline found with antidepressants, it is unlikely that these benefits are of clinical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons
Woolcott, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.357 · Cited by 1,326
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Impact of Anticholinergics on the Aging Brain: A Review and Practical Application
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008) · Aging Health · doi:10.2217/1745509x.4.3.311 · Cited by 862
Sex Differences in the Clinical Manifestations of Alzheimer Disease Pathology
Barnes, L. L., Wilson, R. S., Bienias, J. L., Schneider, J. A., Evans, D. A., & Bennett, D. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.685 · Cited by 643
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398
The Accuracy of Medicare Claims as an Epidemiological Tool: The Case of Dementia Revisited
Taylor, Jr., Østbye, T., Langa, K. M., Weir, D., & Plassman, B. L. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1099 · Cited by 354 · cited 1×
“89.(49) Although information on actual medication ingestion was not available using Medicare claims or the MDS, staff administer NH residents’ medications, so medication use is likely to be reliable.”
MethodFarlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Rosenberg, P. B., Mielke, M. M., Han, D., Leoutsakos, J. S., Lyketsos, C. G., Rabins, P. V., Zandi, P. P., Breitner, J. C. S., Norton, M. C., Welsh‐Bohmer, K. A., et al. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3769 · Cited by 127 · cited 4×
“Typical antipsychotics were associated with more-rapid cognitive decline, but atypical antipsychotics were not.(12) In a retrospective study of outpatients with mild to moderate AD, atypical antipsychotic users had no significant cognitive change over 6 months and demonstrated significant improvements in ADLs and inst…”
BackgroundResultSelf-citationSimoni-Wastila, L., Ryder, P. T., Qian, J., Zuckerman, I. H., Shaffer, T., & Zhao, L. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31819b8936 · Cited by 63
Self-citationCognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease
Munro, C. A., Longmire, C. F., Drye, L. T., Martin, B. K., Frangakis, C. E., Meinert, C. L., Mintzer, J. E., Porsteinsson, A. P., Rabins, P. V., Rosenberg, P. B., et al. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31826ce4c5 · Cited by 49
Self-citation
Cited by
Antidepressant use and cognitive decline in patients with dementia: a national cohort study
Mo, M., Abzhandadze, T., Hoang, M. T., Sacuiu, S., Jurado, P. G., Pereira, J. B., Naia, L., Kele, J., Maioli, S., Xu, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03851-3 · Cited by 45
Smeets, C. H. W., Gerritsen, D. L., Zuidema, S. U., Teerenstra, S., van der Spek, K., Smalbrugge, M., & Koopmans, R. T. C. M. (2018) · Aging & Mental Health · doi:10.1080/13607863.2017.1348469 · Cited by 31
“…rates in our population with the worldwide ranges shown in the introduction, it appears that the prescription rate of APs in our sample is rather average, whereas our rates are relatively low for ADs, anxiolytics, and hypnotics (De Mauleon et al., 2014; Dutcher et al., 2014; Zuidema et al., 2011).”
ResultQin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Metadata
- Authors
- Dutcher, S. K., Rattinger, G. B., Langenberg, P., Chhabra, P. T., Liu, X., Rosenberg, P. B., Leoutsakos, J., Simoni‐Wastila, L., Walker, L. D., Franey, C. S., & Zuckerman, I. H.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2014-05-13
- Volume
- 62
- Issue
- 6
- Pages
- 1046-1055
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2032140625
- Cited by
- 44
- References
- 16
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.